Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;32(3):e2309.
doi: 10.1002/rmv.2309. Epub 2021 Oct 22.

Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities

Zeinab Mohseni Afshar  1 , Arefeh Babazadeh  2 , Alireza Janbakhsh  1 , Feizollah Mansouri  1 , Terence T Sio  3 , Mark J M Sullman  4   5 , Kristin Carson-Chahhoud  6 , Rezvan Hosseinzadeh  7 , Mohammad Barary  7 , Soheil Ebrahimpour  2
Affiliations
Review

Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities

Zeinab Mohseni Afshar et al. Rev Med Virol. 2022 May.

Abstract

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid-19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid-19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end-stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.

Keywords: Covid-19; SARS-CoV-2; efficacy; immunocompromise; safety; vaccination.

PubMed Disclaimer

References

    1. Sadeghi‐Haddad‐Zavareh M, Bayani M, Shokri M, et al. C‐reactive protein as a prognostic indicator in COVID‐19 patients. Interdiscip Perspect Infect Dis. 2021;2021:5557582. doi:10.1155/2021/5557582 - DOI - PMC - PubMed
    1. Eftekhar SP, Kazemi S, Barary M, et al. Effect of hydroxychloroquine and azithromycin on QT interval prolongation and other cardiac arrhythmias in COVID‐19 confirmed patients. Cardiovasc Ther. 2021;2021:6683098. doi:10.1155/2021/6683098 - DOI - PMC - PubMed
    1. Javanian M, Bayani M, Shokri M, et al. Risk factors for mortality of 557 adult patients with COVID 19 in Babol, Northern Iran: a retrospective cohort study. Bratisl Lek Listy. 2021;122(1):34‐38. doi:10.4149/BLL_2021_003 - DOI - PubMed
    1. Incalzi RA, Trevisan C, Del Signore S, et al. Are vaccines against COVID‐19 tailored to the most vulnerable people? Vaccine. 2021;39(17):2325‐2327. - PMC - PubMed
    1. Sonani B, Aslam F, Goyal A, Patel J, Bansal P. COVID‐19 vaccination in immunocompromised patients. Clin Rheumatol. 2021;40(2):797‐798. doi:10.1007/s10067-020-05547-w - DOI - PMC - PubMed

Substances